Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
Johnson and Johnson
Medtronic
Mallinckrodt

Last Updated: September 26, 2022

Details for Patent: 8,101,599


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,101,599
Title:Pharmaceutical composition containing anti-hypertensive agents
Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.
Inventor(s): Shetty; Suraj S (Far Hills, NJ), Webb; Randy L (Flemington, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/338,066
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,101,599
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Device; Use;

Drugs Protected by US Patent 8,101,599

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis EXFORGE HCT amlodipine besylate; hydrochlorothiazide; valsartan TABLET;ORAL 022314-001 Apr 30, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis EXFORGE HCT amlodipine besylate; hydrochlorothiazide; valsartan TABLET;ORAL 022314-002 Apr 30, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis EXFORGE HCT amlodipine besylate; hydrochlorothiazide; valsartan TABLET;ORAL 022314-003 Apr 30, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis EXFORGE HCT amlodipine besylate; hydrochlorothiazide; valsartan TABLET;ORAL 022314-004 Apr 30, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis EXFORGE HCT amlodipine besylate; hydrochlorothiazide; valsartan TABLET;ORAL 022314-005 Apr 30, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,101,599

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 040014 See Plans and Pricing
Austria 429223 See Plans and Pricing
Australia 2003240261 See Plans and Pricing
Brazil 0310092 See Plans and Pricing
Canada 2486144 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKesson
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.